Sodium Iodide [123i] Ge Healthcare

Sodium Iodide [123I] from GE Healthcare is a radiopharmaceutical used in nuclear medicine imaging. This diagnostic agent helps evaluate thyroid function and detect thyroid disorders. It is administered intravenously for precise imaging results. Commonly used in clinical settings for accurate diagnosis.

Sodium Iodide [123I] is primarily used in nuclear medicine imaging to assess thyroid function and identify abnormalities such as nodules or hyperthyroidism. It is also employed in whole-body scans to detect metastatic thyroid cancer. This radiopharmaceutical helps clinicians evaluate iodine uptake in the thyroid gland, aiding in the diagnosis of various thyroid-related conditions. It is not intended for general pain relief or unrelated medical issues.

After administration, Sodium Iodide [123I] is absorbed by the thyroid gland, emitting gamma radiation that is detected by imaging equipment. This process produces detailed images of the thyroid, allowing healthcare providers to assess its structure and function. Patients may experience mild discomfort at the injection site, but the effects are typically temporary and localized.

Sodium Iodide [123I] should only be handled and administered by trained medical professionals in a controlled clinical environment. Patients should inform their healthcare provider of any allergies, especially to iodine or shellfish, as well as any recent imaging procedures involving contrast agents. Pregnant or breastfeeding individuals should avoid this radiopharmaceutical unless explicitly advised by a doctor.

Certain medications, such as thyroid hormones, antithyroid drugs, or iodine-containing supplements, may interfere with the uptake of Sodium Iodide [123I]. Patients should disclose all current medications to their healthcare provider before undergoing this imaging procedure. Alcohol and other substances are generally not recommended during the preparation and recovery phases.